Genmab A/S
Company Announcement
Agreement for Daratumumab Receives Antitrust Clearance
Company Announcement
-- Daratumumab license agreement with Janssen Biotech, Inc., one of the
Janssen Pharmaceutical Companies of Johnson & Johnson, receives
antitrust clearance
-- License agreement has now become effective
-- Issue of new Genmab shares to Johnson & Johnson Development Corporation
pursuant to a subscription agreement is subject to formal approval of a
private placement prospectus
Copenhagen, Denmark; September 21, 2012 – Genmab A/S (OMX: GEN) announced today
that the worldwide license agreement for daratumumab with Janssen Biotech,
Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has
received antitrust clearance from the Federal Trade Commission and the
Antitrust Division of the Department of Justice under the Hart-Scott-Rodino
Act. This means that the license agreement has now become effective. A private
placement prospectus containing details of the issue of new Genmab shares to
Johnson & Johnson Development Corporation in connection with the agreement has
been prepared in accordance with the applicable rules and regulations and filed
with the Danish Financial Supervisory Authority. Upon the agency's approval,
the new Genmab shares will be registered with the Danish Business Authority by
way of a capital increase in Genmab and subsequently admitted to official
listing and trading on the NASDAQ OMX Copenhagen A/S, after which the
subscription agreement will be considered effective. The license agreement with
Janssen Biotech, Inc. was first announced on August 30, 2012 (Company
Announcements 20 and 21).
About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing
activity. Daratumumab is in clinical development for multiple myeloma (MM).
Daratumumab targets the CD38 molecule which is highly expressed on the surface
of multiple myeloma cells. Daratumumab could also have potential in other
cancers on which CD38 is expressed, including diffuse large B-cell lymphoma,
chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell
leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax®-EGFr;
HuMax®-IL8; HuMax®-TAC; HuMax®-CD38; HuMax®-TF; HuMax®-TF-ADC; HuMax®-Her2;
HuMax®-cMet, HuMax®-CD74, DuoBody™ and UniBody® are all trademarks of Genmab
A/S. Arzerra® is a trademark of GlaxoSmithKline.
Company Announcement no. 22
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=522401&messageId=642249
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=404349